• 1. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 2. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 3. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 4. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 5. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyridines Imidazopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyridines

Research Brief on 7-chloroimidazo[1,5-a]pyridine-3-carboxylic acid (CAS: 1159830-91-7)

7-chloroimidazo[1,5-a]pyridine-3-carboxylic acid (CAS: 1159830-91-7) is a heterocyclic compound that has garnered significant attention in recent pharmaceutical and medicinal chemistry research due to its potential as a versatile scaffold for drug development. This brief synthesizes the latest findings on this compound, focusing on its synthetic routes, biological activities, and therapeutic applications.

The compound belongs to the imidazopyridine class, which is known for its broad pharmacological properties. Recent studies have highlighted its role as a key intermediate in the synthesis of bioactive molecules targeting various disease pathways. The presence of both chloro and carboxylic acid functional groups at positions 7 and 3, respectively, makes it a valuable building block for further chemical modifications.

In terms of synthesis, recent advancements have focused on optimizing the yield and purity of 7-chloroimidazo[1,5-a]pyridine-3-carboxylic acid. A 2023 study published in the Journal of Medicinal Chemistry reported an improved synthetic route using palladium-catalyzed cross-coupling reactions, achieving a 78% yield with high purity (>99%). This represents a significant improvement over traditional methods that often resulted in lower yields and required extensive purification steps.

From a biological perspective, research has demonstrated that derivatives of this compound exhibit promising activity against various molecular targets. Notably, a 2024 study in Bioorganic & Medicinal Chemistry Letters identified several potent analogs showing nanomolar inhibition of protein kinases involved in inflammatory pathways. The carboxylic acid moiety appears crucial for binding interactions, while the chloro substituent enhances metabolic stability.

The compound's potential therapeutic applications are being explored across multiple disease areas. In oncology, researchers have developed PROTAC molecules incorporating this scaffold that effectively degrade oncogenic proteins. In neuroscience, analogs have shown modulation of GABA receptors, suggesting potential for treating anxiety disorders. The versatility of 7-chloroimidazo[1,5-a]pyridine-3-carboxylic acid as a building block continues to drive innovation in drug discovery programs.

Recent patent filings (2023-2024) indicate growing commercial interest in this compound, particularly in the development of kinase inhibitors and antiviral agents. Its stability profile and synthetic accessibility make it attractive for pharmaceutical development. However, challenges remain in optimizing the pharmacokinetic properties of its derivatives, particularly regarding oral bioavailability.

Future research directions include exploring novel synthetic methodologies to access diverse analogs, conducting comprehensive structure-activity relationship studies, and investigating potential combination therapies. The compound's unique chemical features position it as a valuable tool for medicinal chemists seeking to develop next-generation therapeutics across multiple therapeutic areas.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)